Fremont, California, July 6, 2020 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices has completed the acquisition of ophthalmic assets from Molteno Ophthalmic Limited (Molteno), including the proprietary Molteno3® platform. glaucoma drainage device (GDD).
Supported by more than 50 years of scientific and clinical research and implanted in thousands of patients worldwide, the Molteno3® GDD platform has been clinically validated to deliver consistent, long-term reduction in intraocular pressure (IOP) in cases of severe or complex glaucoma.
It has also been shown to offer the benefit of increased efficiency in practice through shorter surgical time.
